“Our Experiences with Erlotinib in Second and Third Line Treatment Patients with Advanced Stage Iiib/ Iv Non-Small Cell Lung Cancer” (2008) Biomolecules and Biomedicine, 8(4), pp. 386–390. doi:10.17305/bjbms.2008.2905.